Literature DB >> 1952824

Anterior callosotomy in the treatment of medically intractable epilepsies: a study of 43 patients with a mean follow-up of 39 months.

H Oguni1, A Olivier, F Andermann, J Comair.   

Abstract

We studied the effectiveness of anterior callosotomy in 43 patients whose follow-up period averaged 39 months. These patients had intractable generalized seizures, characterized by a combination of seizure patterns, most frequently drop attacks with generalized tonic-clonic, generalized tonic, and absence seizures. Overall, drop attacks were the most frequent (31/43 or 72%) and the most disabling seizure pattern (27/43 or 63%); they were also the most likely to benefit from anterior callosotomy (70%). Patients with lateralized changes tended to have a better result than did those without lateralization, but patients with synchronous and symmetrical spike and wave discharges also benefited. The preoperative intelligence quotient and the etiological factors were not predictors of outcome. There was a correlation between the extent of section and the results; patients with section of the anterior two thirds had a better result, compared with those who had section of the anterior half.

Entities:  

Mesh:

Year:  1991        PMID: 1952824     DOI: 10.1002/ana.410300307

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  15 in total

1.  Eyebrow incision with supraorbital trephination for endoscopic corpus callosotomy: a feasibility study.

Authors:  R Shane Tubbs; Matthew D Smyth; George Salter; Kyle Doughty; Jeffrey P Blount
Journal:  Childs Nerv Syst       Date:  2004-01-23       Impact factor: 1.475

Review 2.  Corpus callosotomy in children and the disconnection syndromes: a review.

Authors:  Andrew Jea; Shobhan Vachhrajani; Elysa Widjaja; Daniel Nilsson; Charles Raybaud; Manohar Shroff; James T Rutka
Journal:  Childs Nerv Syst       Date:  2008-03-29       Impact factor: 1.475

Review 3.  Rates and predictors of seizure outcome after corpus callosotomy for drug-resistant epilepsy: a meta-analysis.

Authors:  Alvin Y Chan; John D Rolston; Brian Lee; Sumeet Vadera; Dario J Englot
Journal:  J Neurosurg       Date:  2018-05-01       Impact factor: 5.115

4.  Epileptic drop attacks in partial epilepsy: clinical features, evolution, and prognosis.

Authors:  P Tinuper; A Cerullo; C Marini; P Avoni; A Rosati; R Riva; A Baruzzi; E Lugaresi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

5.  Gamma knife radiosurgery for callosotomy in children with drug-resistant epilepsy.

Authors:  Hans Georg Eder; Michael Feichtinger; Tom Pieper; Senta Kurschel; Oskar Schroettner
Journal:  Childs Nerv Syst       Date:  2006-06-13       Impact factor: 1.475

Review 6.  Vagus nerve stimulation vs. corpus callosotomy in the treatment of Lennox-Gastaut syndrome: a meta-analysis.

Authors:  Guido Lancman; Michael Virk; Huibo Shao; Madhu Mazumdar; Jeffrey P Greenfield; Steven Weinstein; Theodore H Schwartz
Journal:  Seizure       Date:  2012-10-12       Impact factor: 3.184

7.  Anterior callosotomy in the management of intractable epileptic seizures: significance of the extent of resection.

Authors:  D E Sakas; J Phillips
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

8.  Callosotomy for severe epilepsies with generalized seizures: outcome and prognostic factors.

Authors:  G F Rossi; G Colicchio; E Marchese; A Pompucci
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

9.  Outcome and long term follow-up after corpus callosotomy in childhood onset intractable epilepsy.

Authors:  Güzide Turanli; Dilek Yalnizoğlu; Demet Genç-Açikgöz; Nejat Akalan; Meral Topçu
Journal:  Childs Nerv Syst       Date:  2006-03-14       Impact factor: 1.475

Review 10.  Corpus callosotomy versus vagus nerve stimulation for atonic seizures and drop attacks: A systematic review.

Authors:  John D Rolston; Dario J Englot; Doris D Wang; Paul A Garcia; Edward F Chang
Journal:  Epilepsy Behav       Date:  2015-08-03       Impact factor: 2.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.